Merck: FDA approves new indication for Keytruda

(CercleFinance.com) - Merck has announced that the US FDA has approved Keytruda as an adjuvant treatment after surgical resection and platinum-based chemotherapy for adult patients with stage IB, II or IIIA non-small cell lung cancer (NSCLC).


The approval is based on data from a pivotal Phase 3 trial that showed the Keytruda protocol of care reduced the risk of disease recurrence or death by 27% compared to placebo.

The median recurrence-free survival time was nearly five years (58.7 months) for the Keytruda arm versus nearly three years (34.9 months) for the placebo arm, the company said.


Copyright (c) 2023 CercleFinance.com. All rights reserved.